Printer Friendly

BELMAC APPOINTS FORMER SMITHKLINE BEECHAM EXECUTIVE AS NEW PRESIDENT AND CHIEF EXECUTIVE OFFICER

 TAMPA, Fla., Aug. 10 /PRNewswire/ -- Belmac Corporation (AMEX: BLM) announced today that the board of directors has appointed Donald E. Boultbee as president and chief executive officer of Belmac. His 20 years of top-level management and marketing experience with SmithKline Beecham will be very beneficial to Belmac's new strategic direction.
 Boultbee served as area vice president for Latin America, and certain Middle East and Far East markets for SmithKline Beecham, Philadelphia, where he was responsible for $400 million in sales, primarily prescription pharmaceuticals. He also held management positions with SmithKline Beecham in Europe, Africa and Asia. He played a leadership role in SmithKline Beecham's effort to re-emphasize the significant potential of "Augmentin" (amoxicillin/clavulanate potassium) in overcoming the increasing resistance of micro-organisms to penicillin and cephalosporin classes of antibiotics.
 He also pioneered sales of "Engerix-B", the recombinant hepatitis B vaccine in many countries prior to its U.S. launch by emphasizing the costs-to-benefits ratio to prophylactic treatment against this damaging virus.
 Most recently, Boultbee has served as a strategic planning consultant with major pharmaceutical companies and biotech firms, and as a director of Euromedia.
 Ranald Stewart Jr., Belmac's chairman of the board, said, "We are very excited to be able to attract someone of Mr. Boultbee's caliber and recognized experience to Belmac. With the benefit of his guidance, we have a team with a very promising future." Belmac's most promising product is a newly patented formulation of erythromycin (Biolid(R)), which is more readily absorbed than other erythromycin products, and can consequently be administered in lower doses, with potentially fewer side effects at a lower cost. Therefore, Boultbee's management and marketing experience is specifically relevant to Belmac.
 Belmac Corporation is an international pharmaceutical and healthcare company based in Tampa, Fla.
 -0- 8/10/93
 /CONTACT: Jill Figueredo of Belmac Corporation, 813-286-4401/
 (BLM)


CO: Belmac Corporation ST: Florida IN: MTC SU: PER

AW-PC -- FL003 -- 1056 08/10/93 08:59 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 10, 1993
Words:320
Previous Article:CEL-SCI CORPORATION ANNOUNCES THE ADDITION OF A NEW MEMBER TO ITS SCIENTIFIC ADVISORY BOARD
Next Article:EQUIFAX ACQUIRES INTEGRATEC, INC.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters